NBIX•benzinga•
Neurocrine Biosciences To Present One-Year Data From Phase 3 CAHtalyst Pediatric Study At PES 2025, Showing Lasting Reductions In Glucocorticoid Doses Who Received CRENESSITY
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 16, 2025 by benzinga